Coronavirus vaccine update: Almost a year after the highly contagious coronavirus hit the world, hopes of getting an effective vaccine soon have been raised with Pfizer, Moderna, Russia's Sputnik V, India's 'Covaxin' and the Oxford vaccine showing promising results at different stages of trials. The global Covid-19 tally has surged past 52 million and 1.2 million had died so far. The US, which is the worst-hit country, plans to start distribution of vaccines by December. Along with the US, India, France, Russia and Brazil are struggling to curb the spread of the virus.
Take a look at how things stand:
* There are at least 182 coronavirus vaccine candidates in pre-clinical or clinical-trial stages across the globe at present.
* Nine vaccine candidates are in the final human-trial stage.
* In India, two vaccines are in Phase-II trials and one (the Oxford University one) in Phase-III.
Covid vaccine progress
1. India coronavirus update: SII and ICMR complete enrolment of phase 3 trials for Oxford vaccine Covishield
Serum Institute of India (SII) and ICMR on Thursday announced the completion of enrolment process of 1,600 participants in the phase-III clinical trials for COVID-19 vaccine Covishield in the country.
SII and the Indian Council of Medical Research (ICMR) are collaborating on the clinical trials of the vaccine in the country.
2. Coronavirus vaccine: Pfizer shot said to cause face pain, hangover
Volunteers on the Pfizer vaccine trial have compared the jab's side effects to a 'severe hangover' and said it left them with headaches, fever and muscle aches similar to the flu vaccine, the Daily Mail reported.
One 45-year-old volunteer said the first dose left her suffering side effects similar to the flu jab but that her symptoms were 'more severe' after her second jab.
Another volunteer, 44-year-old Glenn Deshields, said Pfizer's vaccine made him feel like he had a 'severe hangover' but that symptoms quickly cleared up.
The Russian 'Sputnik V' vaccine for Covid-19 has arrived in India following the nod to Pharma major Dr Reddy's Laboratories to conduct an adaptive phase 2/3 human clinical trial for the vaccine in the country.
In a video that surfaced on media, containers with logos of Dr Reddy's and Sputnik V being unloaded from a small truck was seen.
4. 20 million Americans could be corona vaccine by December
Roughly 20 million people could be vaccinated against the coronavirus in December, the chief of the Donald Trump administration's vaccine coordination program said today. Anywhere from 25 to 30 million people could be vaccinated each month afterward. The speed depends on a big 'if' - the US Food and Drug Administration's emergency use authorization for one or more vaccines.
5. Brazil says Chinese vaccine trial can resume
Brazil health regulator Anvisa on Wednesday allowed the resumption of late-stage clinical trials for China's Sinovac Covid-19 vaccine, which had been suspended due to the death of a study subject registered in Sao Paulo by suicide.
Moderna Inc said on Wednesday it was on track to report early data from a late-stage trial of its experimental coronavirus vaccine later this month, two days after successful interim data from rival Pfizer Inc’s vaccine. A high degree of effectiveness for the vaccine would make sense as it was "almost identical" to the Pfizer shot, Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said at a conference organised by the Financial Times.
"It may not be 95 per cent, it might be 90 per cent, or 96 per cent, or 89 per cent, but it is going to be up there," he said.
7. India coronavirus vaccine update
The trial of Bharat Biotech-developed coronavirus vaccine candidate 'Covaxin' entered the third phase at Aligarh Muslim University (AMU) on Tuesday and Vice-Chancellor Professor Tariq Mansoor got himself registered to be the first volunteer for the same.
Covaxin Phase-III trial was aimed at evaluating the safety and efficacy of the coronavirus vaccine study led in collaboration with the Indian Council of Medical Research (ICMR) and Bharat Biotech, a release from AMU stated.
BioNTech, the first in the race to disclose interim data from a large-scale trial showing a highly effective Covid-19 vaccine, is planning to price the two-shot regimen below "typical market rates" and would differentiate pricing between countries and regions.
9. China coronavirus vaccine update
China National Pharmaceutical Group (Sinopharm) said on Wednesday that the data from large-scale, late-stage clinical trials for its unit's Covid-19 vaccine were "better than expected". Sinopharm's unit China National Biotec Group (CNBG) has moved two vaccine candidates into Phase-III clinical trials outside China in multiple countries, including the United Arab Emirates, Bahrain and Egypt involving more 50,000 participants in total.
The trials were nearing their end, Sinopharm said in a statement on Chinese social media WeChat.
10. Canada coronavirus vaccine progress
Canadian drug developer Medicago said a combination of its experimental Covid-19 vaccine and GlaxoSmithKline's vaccine booster produced virus-neutralising antibodies in all healthy volunteers in an early-stage study. The company, which is backed by Mitsubishi Tanabe Pharma and tobacco giant Philip Morris, said it planned to move into mid-to-late-stage trials with a lower dose version of its vaccine, along with the GSK adjuvant.
8:59 AM IST Assam reports three more coronavirus deaths, 328 new cases. Infection tally rises to 2,09,835, death toll reaches 957. The state currently has 4,799 active cases of the disease.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.